The pill, known as PF-07321332 or Paxlovid, is to be given in combination with an older antiviral drug called ritonavir. Earlier this month Pfizer announced topline results from its trial saying that an interim analysis — done before the trial was scheduled to end — showed an 89% reduction in the risk of hospitalization or death from Covid-19 among people given the drug within the first three days of symptom onset. "Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization," Pfizer said in the statement.